Chronic plaque psoriasis market seen reaching $30.99 billion by 2030
The chronic plaque psoriasis market is projected to grow from $22.26 billion in 2025 to $30.99 billion by 2030, driven by better diagnosis, wider treatment access and new biologic and oral therapies. North America led in 2025, while Asia-Pacific is expected to post the fastest growth.
Why it matters: - Chronic plaque psoriasis treatment demand is rising as more patients are diagnosed and more therapies reach the market. - The market’s projected climb to $30.99 billion by 2030 signals sustained spending on autoimmune and dermatology care. - The growth outlook also points to continued investment in biologics, oral immunomodulators and personalized dermatology.
What happened: - The Business Research Company released its Chronic Plaque Psoriasis Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the market is expected to grow from $22.26 billion in 2025 to $23.83 billion in 2026. - The report forecasts the market will reach $30.99 billion by 2030. - The report was distributed from London on Nov. 18, 2026. - The company made a free sample of the report available. - The company also posted the full report.
The details: - The report estimates a 7.1% compound annual growth rate from 2025 to 2026. - It projects a 6.8% CAGR through 2030. - Historical growth is tied to better diagnosis of autoimmune skin disorders, wider availability of topical treatments, greater awareness of psoriasis management, more dermatology clinics and improved access to specialty medications. - Future growth is supported by next-generation biologic therapies, broader use of oral immunomodulators, personalized dermatology approaches, patient-focused care and more autoimmune disease research. - The report identifies growing preference for biologic treatments, increased use of targeted small molecule drugs, expansion of oral medication options and longer-term disease management as key trends. - Chronic plaque psoriasis is a long-lasting inflammatory skin disorder marked by raised red patches with silvery-white scales. - The condition typically affects the scalp, elbows, knees and lower back, but it can appear anywhere on the body. - The disease stems from an autoimmune reaction that speeds up skin cell turnover and causes inflammation and discomfort. - The report says rising immune system dysfunction is a major market driver. - Immune dysfunction can increase vulnerability to infections, autoimmune diseases and cancer. - Genetic factors, environmental triggers, malnutrition, chronic stress, autoimmune disease prevalence and infections such as HIV are linked to rising immune dysfunction cases. - The report cites Arthritis Australia data from February 2024 showing projected rheumatoid arthritis cases of about 212,136 males and 362,137 females in 2025, rising to about 280,040 males and 479,828 females by 2040. - North America held the largest share of the market in 2025. - North America’s lead is tied to established healthcare infrastructure, strong research activity and high patient awareness. - Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.
Between the lines: - The market outlook suggests psoriasis care is shifting toward more targeted, longer-duration treatment strategies. - Regional growth outside North America could widen as access to diagnosis and specialty care improves. - The report’s emphasis on immune dysregulation shows psoriasis demand is being shaped by broader autoimmune disease trends, not just dermatology alone.
What's next: - Market growth will likely track adoption of biologics, oral therapies and personalized treatment plans. - Asia-Pacific could narrow the gap with North America if healthcare access and diagnosis rates continue improving. - The Business Research Company is positioning its 2026 market reports with added forecasting dashboards, TAM analysis, company scoring tools and updated graphics.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthy Living Europe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.